Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Macrophage Pharma Ltd.

Headquarters: Windsor, United Kingdom
Year Founded: 2016
Status: Private

BioCentury | Dec 15, 2022
Management Tracks

Debra Yu leaving LianBio

Plus: Bayer vet Weinand appointed chair at Umoja, and updates from vTv, Gradalis, Generate and more
BioCentury | Oct 21, 2019
Emerging Company Profile

Verseau unveils tumor macrophage reprogramming strategy

Verseau debuts with $50M, therapies that make tumor-associated macrophages pro-inflammatory
BioCentury | Mar 14, 2019
Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

How Silverback’s conjugates activate tumor-specific myeloid cells against cancer
BioCentury | Mar 8, 2019
Targets & Mechanisms

Flipping the switch in immuno-oncology

Turning suppressive myeloid cells in tumors into immune-activating ones
BioCentury | Sep 1, 2017
Financial News

Macrophage raises L3M to close L12M series A

BioCentury | May 18, 2017
Emerging Company Profile

Spreading Carma

Carma Therapeutics uses CAR macrophages to eat up solid tumors
BioCentury | Apr 13, 2017
Translation in Brief

Eating cancer

How HDAC inhibitors turn immunosuppressive macrophages against tumors
BioCentury | Jan 20, 2017
Company News

Chroma, Macrophage deal

Items per page:
1 - 10 of 11